Fate Therapeutics’ FT522 shows efficacy in Phase 2 B-cell lymphoma trial

Fate Therapeutics (FATE) presented initial clinical and translational data from the company’s Phase 1 study of FT522 in relapsed / refractory B-cell lymphoma at the American College of Rheumatology Convergence in Washington, D.C. FT522 is the company’s off-the-shelf, CD19-targeted chimeric antigen receptor – CAR – natural killer – NK – cell product candidate that incorporates multiple novel synthetic controls of cell function designed to target and deplete pathogenic immune cells, and is the company’s first product candidate to integrate its alloimmune defense receptor technology to enable effective treatment of patients without administration of intense conditioning chemotherapy. The Phase 1 basket study for B cell-mediated autoimmune diseases is designed to assess FT522 as add-on to standard-of-care induction and maintenance regimens without conditioning chemotherapy. Initial Phase 1 clinical data in relapsed / refractory B-cell lymphoma show favorable safety profile, complete responses, and persistence of FT522 live cells. Selective targeting and reduction of CD19+ B cells was observed with each FT522 dose in the study’s first low-dose cohort without conditioning chemotherapy, supporting novel ADR technology.